Physician profile
Daniel Yarrish
NPI 1235240110
$889.11
in general payments reported to CMS, 2019-2025
20 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.01 · 2020: $50.87 · 2021: $33.93 · 2022: $141 · 2023: $299 · 2024: $132 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $197.07 | 2023-2025 | Vraylar |
| Abbott Laboratories | $101.82 | 2021-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $92.54 | 2022-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $84.68 | 2019-2025 | |
| Glaxosmithkline, LLC. | $46.01 | 2024-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $41.19 | 2023 | Veozah |
| Rgh Enterprises LLC | $37.61 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $36.73 | 2020-2023 | Farxiga |
| Dexcom, INC. | $35.18 | 2019-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $30.23 | 2019-2021 | |
| Boston Scientific Corporation | $27.33 | 2020 | |
| Eisai INC. | $26.25 | 2024 | |
| Xeris Pharmaceuticals, INC. | $24.29 | 2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $17.73 | 2022 | |
| Gilead Sciences, INC. | $17.64 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $16.18 | 2023 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $15.42 | 2023 | Gemtesa |
| Becton, Dickinson and Company | $14.93 | 2025 | Bd Onclarity |
| Sunovion Pharmaceuticals INC. | $13.48 | 2022 | |
| Lilly USA, LLC | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Yarrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.